checkAd
    Reviva Pharmaceuticals Holdings Aktie
    1,7100
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 16.05.24 Nasdaq
    1,7100
     
    USD
    2.700 STK
    Geldkurs 16.05.24
    1,7300
     
    USD
    1.400 STK
    Briefkurs 16.05.24
    ISIN: US76152G1004 · WKN: A2QK7Q · SYM: RVPH · USA

    Neueste Nachrichten

    Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
    15.05.24 · globenewswire · Reviva Pharmaceuticals Holdings
    Die größten Aufsteiger der Woche vom 08.05.-15.05.2024 in der wO Community
    15.05.24 · wO Chartvergleich · Bayer
    Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
    14.05.24 · globenewswire · Reviva Pharmaceuticals Holdings
    Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
    13.05.24 · globenewswire · Reviva Pharmaceuticals Holdings
    Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
    09.05.24 · globenewswire · Reviva Pharmaceuticals Holdings
    RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
    25.04.24 · Business Wire (engl.) · Reviva Pharmaceuticals Holdings
    Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
    15.04.24 · globenewswire · Reviva Pharmaceuticals Holdings
    Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
    15.04.24 · globenewswire · Reviva Pharmaceuticals Holdings
    Die größten Aufsteiger der Woche vom 27.03.-03.04.2024 in der wO Community
    03.04.24 · wO Chartvergleich · Borussia Dortmund
    Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
    28.03.24 · globenewswire · Reviva Pharmaceuticals Holdings
    Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
    26.03.24 · globenewswire · Reviva Pharmaceuticals Holdings
    Reviva to Present at the UBS Virtual CNS Day
    11.03.24 · globenewswire · Reviva Pharmaceuticals Holdings